Interacciones de Fenilacetato de sodio y benzoato de sodio
Fenilacetato de sodio y benzoato de sodio (Ammonul) tiene 49 interacciones documentadas en las etiquetas de la FDA y las hojas informativas que indexamos. Graves: 0; moderadas: 36; leves: 13; casos en los que una etiqueta indica que no hay ninguna interacción significativa: 0. Cada entrada de abajo cita la frase que la respalda. Esta página del medicamento es un punto de partida, no un veredicto sobre su situación.
Interacciones según la etiqueta
Interacciones moderadas (36)
Hyperventilation and Metabolic Acidosis: Sodium Phenylacetate and Sodium Benzoate Injection may cause side effects typically associated with salicylate overdose, such as hyperventilation and metabolic acidosis. (etiqueta de Fenilacetato de sodio y benzoato de sodio, Advertencias y precauciones)
Hyperventilation and Metabolic Acidosis: Sodium Phenylacetate and Sodium Benzoate Injection may cause side effects typically associated with salicylate overdose, such as hyperventilation and metabolic acidosis. (etiqueta de Fenilacetato de sodio y benzoato de sodio, Advertencias y precauciones)
Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (etiqueta de Fenilacetato de sodio y benzoato de sodio, Interacciones medicamentosas)
Hyperventilation and Metabolic Acidosis: Sodium Phenylacetate and Sodium Benzoate Injection may cause side effects typically associated with salicylate overdose, such as hyperventilation and metabolic acidosis. (etiqueta de Fenilacetato de sodio y benzoato de sodio, Advertencias y precauciones)
Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (etiqueta de Fenilacetato de sodio y benzoato de sodio, Interacciones medicamentosas)
Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (etiqueta de Fenilacetato de sodio y benzoato de sodio, Interacciones medicamentosas)
Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (etiqueta de Fenilacetato de sodio y benzoato de sodio, Interacciones medicamentosas)
Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (etiqueta de Fenilacetato de sodio y benzoato de sodio, Interacciones medicamentosas)
Hyperventilation and Metabolic Acidosis: Sodium Phenylacetate and Sodium Benzoate Injection may cause side effects typically associated with salicylate overdose, such as hyperventilation and metabolic acidosis. (etiqueta de Fenilacetato de sodio y benzoato de sodio, Advertencias y precauciones)
Hyperventilation and Metabolic Acidosis: Sodium Phenylacetate and Sodium Benzoate Injection may cause side effects typically associated with salicylate overdose, such as hyperventilation and metabolic acidosis. (etiqueta de Fenilacetato de sodio y benzoato de sodio, Advertencias y precauciones)
Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (etiqueta de Fenilacetato de sodio y benzoato de sodio, Interacciones medicamentosas)
Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (etiqueta de Fenilacetato de sodio y benzoato de sodio, Interacciones medicamentosas)
Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (etiqueta de Fenilacetato de sodio y benzoato de sodio, Interacciones medicamentosas)
Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (etiqueta de Fenilacetato de sodio y benzoato de sodio, Interacciones medicamentosas)
Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (etiqueta de Fenilacetato de sodio y benzoato de sodio, Interacciones medicamentosas)
Hyperventilation and Metabolic Acidosis: Sodium Phenylacetate and Sodium Benzoate Injection may cause side effects typically associated with salicylate overdose, such as hyperventilation and metabolic acidosis. (etiqueta de Fenilacetato de sodio y benzoato de sodio, Advertencias y precauciones)
- Fenilbutirato de glicerolModerada
In a study of adult cancer patients, subjects received sodium phenylacetate administered as a 1-hour infusion twice daily at two dose levels of 125 and 150 mg/kg for a 2-week period. (etiqueta de Fenilbutirato de glicerol, Advertencias y precauciones)
Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (etiqueta de Fenilacetato de sodio y benzoato de sodio, Interacciones medicamentosas)
Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (etiqueta de Fenilacetato de sodio y benzoato de sodio, Interacciones medicamentosas)
Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (etiqueta de Fenilacetato de sodio y benzoato de sodio, Interacciones medicamentosas)
Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (etiqueta de Fenilacetato de sodio y benzoato de sodio, Interacciones medicamentosas)
Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (etiqueta de Fenilacetato de sodio y benzoato de sodio, Interacciones medicamentosas)
Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (etiqueta de Fenilacetato de sodio y benzoato de sodio, Interacciones medicamentosas)
Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (etiqueta de Fenilacetato de sodio y benzoato de sodio, Interacciones medicamentosas)
Hyperventilation and Metabolic Acidosis: Sodium Phenylacetate and Sodium Benzoate Injection may cause side effects typically associated with salicylate overdose, such as hyperventilation and metabolic acidosis. (etiqueta de Fenilacetato de sodio y benzoato de sodio, Advertencias y precauciones)
Hyperventilation and Metabolic Acidosis: Sodium Phenylacetate and Sodium Benzoate Injection may cause side effects typically associated with salicylate overdose, such as hyperventilation and metabolic acidosis. (etiqueta de Fenilacetato de sodio y benzoato de sodio, Advertencias y precauciones)
Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (etiqueta de Fenilacetato de sodio y benzoato de sodio, Interacciones medicamentosas)
Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (etiqueta de Fenilacetato de sodio y benzoato de sodio, Interacciones medicamentosas)
Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (etiqueta de Fenilacetato de sodio y benzoato de sodio, Interacciones medicamentosas)
Hyperventilation and Metabolic Acidosis: Sodium Phenylacetate and Sodium Benzoate Injection may cause side effects typically associated with salicylate overdose, such as hyperventilation and metabolic acidosis. (etiqueta de Fenilacetato de sodio y benzoato de sodio, Advertencias y precauciones)
Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (etiqueta de Fenilacetato de sodio y benzoato de sodio, Interacciones medicamentosas)
Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (etiqueta de Fenilacetato de sodio y benzoato de sodio, Interacciones medicamentosas)
Hyperventilation and Metabolic Acidosis: Sodium Phenylacetate and Sodium Benzoate Injection may cause side effects typically associated with salicylate overdose, such as hyperventilation and metabolic acidosis. (etiqueta de Fenilacetato de sodio y benzoato de sodio, Advertencias y precauciones)
Hyperventilation and Metabolic Acidosis: Sodium Phenylacetate and Sodium Benzoate Injection may cause side effects typically associated with salicylate overdose, such as hyperventilation and metabolic acidosis. (etiqueta de Fenilacetato de sodio y benzoato de sodio, Advertencias y precauciones)
Hyperventilation and Metabolic Acidosis: Sodium Phenylacetate and Sodium Benzoate Injection may cause side effects typically associated with salicylate overdose, such as hyperventilation and metabolic acidosis. (etiqueta de Fenilacetato de sodio y benzoato de sodio, Advertencias y precauciones)
Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (etiqueta de Fenilacetato de sodio y benzoato de sodio, Interacciones medicamentosas)
Menciones leves (13)
There have been reports that valproic acid can induce hyperammonemia through inhibition of the synthesis of N-acetylglutamate, a co-factor for carbamyl phosphate synthetase. (etiqueta de Fenilacetato de sodio y benzoato de sodio, Interacciones medicamentosas)
Some antibiotics such as penicillin may compete with phenylacetylglutamine and hippurate for active secretion by renal tubules, which may affect the overall disposition of the infused drug. (etiqueta de Fenilacetato de sodio y benzoato de sodio, Interacciones medicamentosas)
Some antibiotics such as penicillin may compete with phenylacetylglutamine and hippurate for active secretion by renal tubules, which may affect the overall disposition of the infused drug. (etiqueta de Fenilacetato de sodio y benzoato de sodio, Interacciones medicamentosas)
Some antibiotics such as penicillin may compete with phenylacetylglutamine and hippurate for active secretion by renal tubules, which may affect the overall disposition of the infused drug. (etiqueta de Fenilacetato de sodio y benzoato de sodio, Interacciones medicamentosas)
Some antibiotics such as penicillin may compete with phenylacetylglutamine and hippurate for active secretion by renal tubules, which may affect the overall disposition of the infused drug. (etiqueta de Fenilacetato de sodio y benzoato de sodio, Interacciones medicamentosas)
Some antibiotics such as penicillin may compete with phenylacetylglutamine and hippurate for active secretion by renal tubules, which may affect the overall disposition of the infused drug. (etiqueta de Fenilacetato de sodio y benzoato de sodio, Interacciones medicamentosas)
Some antibiotics such as penicillin may compete with phenylacetylglutamine and hippurate for active secretion by renal tubules, which may affect the overall disposition of the infused drug. (etiqueta de Fenilacetato de sodio y benzoato de sodio, Interacciones medicamentosas)
Some antibiotics such as penicillin may compete with phenylacetylglutamine and hippurate for active secretion by renal tubules, which may affect the overall disposition of the infused drug. (etiqueta de Fenilacetato de sodio y benzoato de sodio, Interacciones medicamentosas)
Some antibiotics such as penicillin may compete with phenylacetylglutamine and hippurate for active secretion by renal tubules, which may affect the overall disposition of the infused drug. (etiqueta de Fenilacetato de sodio y benzoato de sodio, Interacciones medicamentosas)
Some antibiotics such as penicillin may compete with phenylacetylglutamine and hippurate for active secretion by renal tubules, which may affect the overall disposition of the infused drug. (etiqueta de Fenilacetato de sodio y benzoato de sodio, Interacciones medicamentosas)
Some antibiotics such as penicillin may compete with phenylacetylglutamine and hippurate for active secretion by renal tubules, which may affect the overall disposition of the infused drug. (etiqueta de Fenilacetato de sodio y benzoato de sodio, Interacciones medicamentosas)
- ProbenecidLeve
Probenecid is known to inhibit the renal transport of many organic compounds, including aminohippuric acid, and may affect renal excretion of phenylacetylglutamine and hippurate. (etiqueta de Fenilacetato de sodio y benzoato de sodio, Interacciones medicamentosas)
Probenecid is known to inhibit the renal transport of many organic compounds, including aminohippuric acid, and may affect renal excretion of phenylacetylglutamine and hippurate. (etiqueta de Fenilacetato de sodio y benzoato de sodio, Interacciones medicamentosas)
Compruebe Fenilacetato de sodio y benzoato de sodio frente a todo lo que toma. Añada su lista completa; todos los pares se comprueban a la vez.
Abrir en el verificadorNo es un consejo médico. La gravedad refleja la redacción de la etiqueta, no sus circunstancias. Una señal «grave» puede ser algo habitual bajo supervisión y una «leve» puede ser importante a dosis altas. Consulte a un farmacéutico.